Frazier Management LLC
- SEC CIK
- 0001032165
- Latest filing
- Nov 14, 2022
Holdings in Q4 2021
Holdings as of Dec 31, 2021, filed Feb 8, 2022. Long positions only; changes compare share counts with Q3 2021.
- Positions
- 43
- +2 vs. Q3 2021
- Portfolio value
- $1.30B
- +$49.1M (+3.9%) vs. Q3 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ARQTArcutis Biotherapeutics, Inc. | COM | 8,434,232 | $174.9M | 13.5% | 00.0% | Unchanged | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 5,827,415 | $114.6M | 8.8% | 00.0% | Unchanged | History |
| IMGOImago BioSciences, Inc. | COM | 2,971,274 | $70.4M | 5.4% | 00.0% | Unchanged | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 2,772,062 | $60.7M | 4.7% | +1,583,927+133.3% | Added | History |
| GRTSGritstone bio, Inc. | COM | 4,667,242 | $60.0M | 4.6% | 00.0% | Unchanged | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 3,566,912 | $56.9M | 4.4% | 00.0% | Unchanged | History |
| PCVXVaxcyte, Inc. | COM | 2,309,554 | $54.9M | 4.2% | 00.0% | Unchanged | History |
| KRYSKrystal Biotech, Inc. | COM | 771,250 | $53.9M | 4.2% | 00.0% | Unchanged | History |
| PRDSPardes Biosciences, Inc. | COM | 2,457,507 | $40.2M | 3.1% | +2,457,507 | New | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 1,384,293 | $39.3M | 3.0% | +532,987+62.6% | Added | History |
| KDNYChinook Therapeutics, Inc. | COM | 2,371,918 | $38.7M | 3.0% | +700,000+41.9% | Added | History |
| BCYCBicycle Therapeutics PLC | SPONSORED ADS | 555,240 | $33.8M | 2.6% | +112,360+25.4% | Added | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 1,747,622 | $33.4M | 2.6% | −926,677−34.7% | Reduced | History |
| TARSTarsus Pharmaceuticals, Inc. | COM | 1,417,157 | $31.9M | 2.5% | 00.0% | Unchanged | History |
| PASGPassage BIO, Inc. | COM | 5,009,219 | $31.8M | 2.4% | 00.0% | Unchanged | History |
| ANABAnaptysbio, Inc | COM | 899,700 | $31.3M | 2.4% | 00.0% | Unchanged | History |
| ISEEIVERIC bio, Inc. | COM | 1,838,402 | $30.7M | 2.4% | 00.0% | Unchanged | History |
| VRDNViridian Therapeutics, Inc. | COM | 1,505,200 | $29.8M | 2.3% | 00.0% | Unchanged | History |
| SRRASierra Oncology, Inc. | COM NEW | 1,264,861 | $27.5M | 2.1% | +460,194+57.2% | Added | History |
| STROSutro Biopharma, Inc. | COM | 1,776,479 | $26.4M | 2.0% | +307,816+21.0% | Added | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 1,784,913 | $24.7M | 1.9% | +13,069+0.7% | Added | History |
| SLNSilence Therapeutics plc | ADS | 886,173 | $21.2M | 1.6% | +886,173 | New | History |
| AUTLAutolus Therapeutics plc | SPON ADS | 3,746,857 | $19.4M | 1.5% | +216,200+6.1% | Added | History |
| MRUSMerus N.V. | COM | 559,179 | $17.8M | 1.4% | +559,179 | New | History |
| REPLReplimune Group, Inc. | COM | 650,862 | $17.6M | 1.4% | +158,864+32.3% | Added | History |
| TYRATyra Biosciences, Inc. | COM | 1,250,000 | $17.6M | 1.4% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,305,087 | $17.3M | 1.3% | +1,148,280+732.3% | Added | History |
| TCDATricida, Inc. | COM | 1,783,893 | $17.1M | 1.3% | +1,783,893 | New | History |
| COGTCogent Biosciences, Inc. | COM | 1,774,891 | $15.2M | 1.2% | +1,774,891 | New | History |
| Frazier Lifesciences Acqu CoG3710A121 | UNIT 12/09/2025 | 1,501,000 | $14.9M | 1.1% | 00.0% | Unchanged | – |
| ARVNArvinas, Inc. | COM | 163,763 | $13.5M | 1.0% | +163,763 | New | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 1,654,938 | $10.0M | 0.8% | +803,300+94.3% | Added | – |
| EPIXESSA Pharma Inc. | COM NEW | 543,470 | $7.72M | 0.6% | +185,124+51.7% | Added | History |
| RGNXREGENXBIO Inc. | COM | 235,809 | $7.71M | 0.6% | 00.0% | Unchanged | History |
| AVDLAvadel Pharmaceuticals PLC | SPONSORED ADR | 951,814 | $7.69M | 0.6% | 00.0% | Unchanged | History |
| ACRSAclaris Therapeutics, Inc. | COM | 408,329 | $5.94M | 0.5% | 00.0% | Unchanged | History |
| MTEMMolecular Templates, Inc. | COM | 1,374,047 | $5.39M | 0.4% | 00.0% | Unchanged | History |
| APTXAptinyx Inc. | COM | 1,883,244 | $5.03M | 0.4% | 00.0% | Unchanged | History |
| IMVTImmunovant, Inc. | COM | 585,759 | $4.99M | 0.4% | 00.0% | Unchanged | History |
| SRRKScholar Rock Holding Corp | COM | 156,000 | $3.88M | 0.3% | 00.0% | Unchanged | History |
| EPZMEpizyme, Inc. | COM | 739,369 | $1.85M | 0.1% | 00.0% | Unchanged | History |
| ALNAAllena Pharmaceuticals, Inc. | COM | 1,651,357 | $978.0K | 0.1% | −1,679,016−50.4% | Reduced | History |
| Nabriva Therapeutics plcG63637113 | SHS | 425,650 | $255.0K | <0.1% | 00.0% | Unchanged | – |
Sold out since Q3 2021 (4)
Positions held at the end of Q3 2021 that are gone from this filing.
| Security | Class | Shares in Q3 2021 | Value in Q3 2021 | % of portfolio in Q3 2021 | History |
|---|---|---|---|---|---|
| Trillium Therapeutics Inc.89620X506 | COM NEW | 3,123,107 | $55.0M | 4.4% | – |
| Bellus Health Inc New07987C204 | COM NEW | 433,247 | $2.65M | 0.2% | – |
| GRTXGalera Therapeutics, Inc. | COM | 241,000 | $1.95M | 0.2% | History |
| Freeline Therapeutics Hldgs35655L107 | SPONSORED ADS | 550,000 | $1.88M | 0.2% | – |